EQUIPALAZONE 200 MG/ML SOLUTION FOR INJECTION
Страна: Ірландія
мова: англійська
Джерело: HPRA (Health Products Regulatory Authority)
Характеристики продукта
(SPC)
20-08-2016
Деякі документи на цей товар наразі недоступні. Ви можете надіслати запит до нашої служби підтримки, і ми повідомимо вас, як тільки ми зможемо їх отримати.
Відправляти запит.
Відправляти запит.
Активний інгредієнт:
PHENYLBUTAZONE
Доступна з:
Dechra Limited
Код атс:
QM01AA01
ІПН (Міжнародна Ім'я):
PHENYLBUTAZONE
Дозування:
200 Mg/Ml
Фармацевтична форма:
Solution for Injection
Тип рецепту:
POM
Терапевтична група:
Equine Non Food
Терапевтична области:
Phenylbutazone
Терапевтичні свідчення:
N.S.A.I.D
Статус Авторизація:
Authorised
Дата Авторизація:
2005-10-01
Характеристики продукта
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Equipalazone 200 mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances
Phenylbutazone
200
mg/ml
Excipients
Benzyl Alcohol
0.015 ml/ml
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless to pale yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and ponies
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of musculo-skeletal disorders in horses and ponies where the anti-inflammatory and analgesic
properties of phenylbutazone can offer relief against inflammation, pain and lameness (for example, osteoarthritis
conditions, acute and chronic laminitis, bursitis and carpitis).
4.3 CONTRAINDICATIONS
The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment.
Do not administer with other non-steroidal anti-inflammatory agents concurrently or within 24 hours of each other.
Do not use in animals suffering from cardiac, hepatic or renal disease; where there is the possibility of gastro-intestinal
ulceration or bleeding; where there is evidence of a blood dyscrasia or of hypersensitivity to the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Discontinue treatment if no response is evident after four to five days treatment.
The clinical effect of phenylbutazone can be evident for at least three days following cessation of administration. This
should be borne in mind when examining horses for soundness.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 05/08/2016_
_CRN 7023797_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTION
Прочитайте повний документ
